1. Home
  2. JYNT vs IPHA Comparison

JYNT vs IPHA Comparison

Compare JYNT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.20

Market Cap

120.7M

Sector

Miscellaneous

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$2.01

Market Cap

131.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JYNT
IPHA
Founded
2010
1999
Country
United States
France
Employees
N/A
163
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.7M
131.4M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
JYNT
IPHA
Price
$8.20
$2.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$17.00
$5.75
AVG Volume (30 Days)
48.5K
118.2K
Earning Date
05-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
133.93
N/A
EPS
0.09
N/A
Revenue
$117,696,356.00
N/A
Revenue This Year
$12.23
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
$91.44
N/A
Revenue Growth
15.49
N/A
52 Week Low
$7.50
$1.18
52 Week High
$13.47
$2.63

Technical Indicators

Market Signals
Indicator
JYNT
IPHA
Relative Strength Index (RSI) 34.04 63.24
Support Level $8.14 $1.69
Resistance Level $8.67 $2.16
Average True Range (ATR) 0.35 0.16
MACD -0.08 0.06
Stochastic Oscillator 6.93 47.05

Price Performance

Historical Comparison
JYNT
IPHA

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: